Masataka Kawana is a Cardiology physician. OpenAlex indexes 52 publications with 2,057 citations (h-index 14); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Pasteur Dr
Stanford, CA 943052200
Telephone
650-723-4000Provider last certified this registry record 22 Apr 2024.
Clinical trials
- Comparison of Noninvasive vs. Invasive Hemodynamic Measurements
Sponsor: Nihon Kohden
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Edwards Lifesciences CorporationProgram year20251 payment
- CVRx, Inc.Program year20251 payment
- Edwards Lifesciences CorporationProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
72.5%Beta blocker16.7%Carvedilol61%Metoprolol Succinate39%Part D≥52 patientsStatin9.8%Atorvastatin Calcium55%Rosuvastatin Calcium45%Part D≥31 patients+ 13 more classes in this area
Metabolism & gastrointestinal
14.7%SGLT2 inhibitor10.4%Jardiance80%Farxiga20%Part D<11 patientsPotassium supplement2.8%Potassium Chloride100%Part D<11 patients+ 1 more class in this area
Blood & clotting
10.1%Factor Xa inhibitor7.7%Eliquis100%Part D≥33 patientsP2Y12 inhibitor1.4%Clopidogrel100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2014–2025 per NIH RePORTER. The latest:
- Functional assessment of atrial myosin mutations in familial atrial arrhythmia
Stanford University
FY2025$231,000R03HL178874 - Bridging the gap between mutation & cellular effects: Defining the mechanisms of hypertrophic cardiomyopathy
Stanford University
FY2023$162,015K08HL145020 - Bridging the gap between mutation & cellular effects: Defining the mechanisms of hypertrophic cardiomyopathy
Stanford University
FY2022$162,015K08HL145020
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”